ATTC candidates — IND submission
2026
HUTCHMED plans to initiate global clinical trials for HMPL-A251 around the end of 2025, followed by multiple global Investigational New Drug (IND) filings for more ATTC candidates in 2026.Source filing
HCM biotech catalysts & pipeline
HUTCHMED (CHINA) LTD · Data as of 2026-10-25
Upcoming catalysts
HMPL-A830 — IND submission
H2 2026
Plans for global clinical trial initiation in H2 2026.Source filing
IMG-007 — Topline data
Q4 2027
Phase IIb trial (NCT07037901) in patients with moderate-to-severe atopic dermatitis progressing, with an amended protocol and topline data anticipated in the fourth quarter of 2027.Source filing
IMG-007 — Initial data
2028
Phase II trial initiation in patients with alopecia areata expected in 2026, with initial data expected in 2028.Source filing
ORPATHYS (savolitinib) plus TAGRISSO (osimertinib) — Conference presentation
Oct 23–Oct 27
These results will be presented in a Presidential Symposium at the upcoming European Society for Medical Oncology (ESMO) Congress 2026.Source filing
savolitinib and osimertinib — Conference presentation
Oct 23–Oct 27
HUTCHMED (China) Limited (" HUTCHMED ") (Nasdaq/AIM:HCM; HKEX:13) today announces that new and updated data from several studies of compounds discovered by HUTCHMED will be presented at the European Society for Medical Oncology ("ESMO") Congress 2026, taking place on October 23-27, 2026, in Madrid, Spain.Source filing